IMUX — Immunic Income Statement
0.000.00%
Last trade - 00:00- $106.36m
- $70.69m
Annual income statement for Immunic, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 49 | 91.7 | 119 | 99.2 | 98.1 |
| Operating Profit | -49 | -91.7 | -119 | -99.2 | -98.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -44 | -92.9 | -120 | -93.6 | -101 |
| Net Income After Taxes | -44 | -92.9 | -120 | -93.6 | -101 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -44 | -92.9 | -120 | -93.6 | -101 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -44 | -92.9 | -120 | -93.6 | -101 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.81 | -3.2 | -2.75 | -2.11 | -1 |